

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

0965 722 720502



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A01N 43/04, A61K 31/70, C12N 15/63	A1	(11) International Publication Number: WO 00/33655 (43) International Publication Date: 15 June 2000 (15.06.00)
(21) International Application Number: PCT/US99/28613 (22) International Filing Date: 3 December 1999 (03.12.99) (30) Priority Data: 60/110,844 4 December 1998 (04.12.98) US (71) Applicant (for all designated States except US): YALE UNIVERSITY [US/US]; 451 College Street, New Haven, CT 06520 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): DEISSEROTH, Albert, P. [US/US]; Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520 (US). CHUNG, Injae [KR/US]; Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520 (US). ZHANG, Lixin [CN/US]; Yale Cancer Center, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520 (US). (74) Agent: TUSCAN, Michael, S.; Morgan, Lewis & Bockius LLP, 1800 M St., NW, Washington, DC 20036 (US).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PLASTIN PROMOTER DIRECTED GENE THERAPY (57) Abstract The invention relates generally to the treatment of cancer using plastin promoter directed gene therapy. The invention includes vectors and recombinant viruses in which a plastin promotor is used to effect the expression of therapeutic transgenes in neoplastic but not in normal epithelial cells.		